Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Genentech

< Previous 1 2 3 4 5 6 Next >

New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)

February 10, 2023

From Genentech

Via Business Wire

Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition

February 07, 2023

From Genentech

Via Business Wire

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

January 19, 2023

From Genentech

Via Business Wire

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

January 06, 2023

From Genentech

Via Business Wire

FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma

December 22, 2022

From Genentech

Via Business Wire

FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults

December 21, 2022

From Genentech

Via Business Wire

Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

December 12, 2022

From Genentech

Via Business Wire

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

December 11, 2022

From Genentech

Via Business Wire

Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth

December 11, 2022

From Genentech

Via Business Wire

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease

November 14, 2022

From Genentech

Via Business Wire

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

November 03, 2022

From Genentech

Via Business Wire

Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)

October 27, 2022

From Genentech

Via Business Wire

Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

October 26, 2022

From Genentech

Via Business Wire

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

October 19, 2022

From Genentech

Via Business Wire

Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)

October 12, 2022

From Genentech

Via Business Wire

FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

August 16, 2022

From Genentech

Via Business Wire

Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older

August 11, 2022

From Genentech

Via Business Wire

Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results

August 02, 2022

From Genentech

Via Business Wire

Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting

July 28, 2022

From Genentech

Via Business Wire

New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration

July 14, 2022

From Genentech

Via Business Wire

New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A

July 11, 2022

From Genentech

Via Business Wire

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

July 06, 2022

From Genentech

Via Business Wire

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

June 16, 2022

From Genentech

Via Business Wire

Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting

June 10, 2022

From Genentech

Via Business Wire

FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)

May 31, 2022

From Genentech

Via Business Wire

New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma

May 26, 2022

From Genentech

Via Business Wire

Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare

May 24, 2022

From Genentech

Via Business Wire

Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

May 11, 2022

From Genentech

Via Business Wire

New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

April 29, 2022

From Genentech

Via Business Wire

New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

April 04, 2022

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.